ClinicalTrials.gg
CompletedNCT03953196Updated Feb 3, 2025

A Study Exploring the Use of Vaccine and Antigen Challenges for Immune Monitoring in Healthy Participants

An Early Phase 1 interventional study of Imvanex and Shingrix in Healthy, sponsored by Janssen Research & Development, LLC. Completed at 1 site in Belgium. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-03.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Early Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Dec 2019, 6 years 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
48
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to characterize the immune response in vivo using approved vaccines and antigen challenges, as well as a skin wounding challenge to stimulate the immune system.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.

Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a (BMI) between 18 and 30 kilogram per square meter (kg/m\^2) (BMI = weight/height\^2), inclusive, and a body weight of no less than 50 kilogram (kg)
  • Healthy on the basis of physical examination, medical history, vital signs, and 12-lead (ECG) (for Cohort 3) performed at screening. Any abnormalities, must be considered not and this determination must be recorded in the participant's source documents and initialed by the investigator
  • Healthy on the basis of clinical laboratory tests performed at screening. If the results of the serum chemistry panel, blood coagulation, hematology, or urinalysis are outside the normal reference ranges, the participant may be included only if the investigator judges the abnormalities or deviations from normal to be not clinically significant. This determination must be recorded in the participant's source documents and initialed by the investigator
  • Must sign an form (ICF) indicating that he or she understands the purpose of, and procedures required for, the study and is willing to participate in the study
  • All women must have a negative highly sensitive serum (Beta-human chorionic gonadotropin [Beta-hCG]) pregnancy test at screening and a negative urine pregnancy test predose on Day 1

Exclusion criteria

Exclusion Criteria:

  • History of any type of immunodeficiency or disease or disease treatment associated with immune suppression or lymphopenia. These include but are not limited to bone marrow or organ transplantation, lymphoproliferative disorders, T- or B-cell deficiency syndromes, splenectomy, functional asplenia and chronic granulomatous disease
  • History of liver or renal insufficiency, significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, bleeding disorders, rheumatologic, psychiatric, or metabolic disturbances, and atopic dermatitis
  • Known allergies, , or intolerance to any of the interventions in this study or their
  • History of severe allergic reaction, angioedema, or anaphylaxis to drugs or food
  • to the use of any of the study interventions per prescribing information
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Early Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Cohort 1: Vaccine Challenge Imvanex

    Participants will receive single dose of Imvanex subcutaneously on Day 1. Participants will also be included in the DREEM EEG substudy.

    Biological: Imvanex

  • Experimental
    Cohort 2: Vaccine Challenge Shingrix

    Participants will receive single dose of Shingrix intramuscularly on Day 1. Participants will also be included in the DREEM EEG substudy.

    Biological: Shingrix

  • Experimental
    Cohort 3: Antigen Challenge Lipopolysaccharides (LPS)

    Participants will receive a single dose of LPS intravenously (IV) on Day 1. Participants will also be included in the DREEM EEG substudy and vital patch physIQ platform substudy.

    Biological: LPS

  • Experimental
    Cohort 4: Antigen Challenge Candin

    Participants will receive one single injection of Candin and one single injection of saline control intradermally on Day 1. Participants will also be included in the DREEM EEG substudy.

    Biological: Candin · Other: Saline Control

  • Experimental
    Cohort 5: Skin Wounding Challenge

    3 punch biopsies will be performed per standard dermatologic practice guidelines. Lower abdomen tissue biopsy specimens will be collected on Day 1.

    Other: Skin Biopsy

Interventions

  • BiologicalImvanex

    Imvanex 0.5 milliliter (mL) suspension for injection will be administered as single subcutaneous (SC) injection.

    Also known as: Imvamune

  • BiologicalShingrix

    Shingrix 0.5 mL suspension will be administered as single intramuscular (IM) injection.

  • BiologicalLPS

    LPS 1.0 nanogram per kilogram (ng/kg) endotoxin suspension will be administered as single IV injection.

    Also known as: Endotoxin

  • BiologicalCandin

    Candin 0.1 mL solution for injection will be administered as one intradermal injection.

    Also known as: Candida albicans

  • OtherSkin Biopsy

    3 punch biopsies will be performed and lower abdomen tissue biopsy specimens will be collected on Day 1.

  • OtherSaline Control

    Saline control solution for injection will be administered as one intradermal injection.

06

What researchers measure

Primary outcomes

  1. Cohort 1 and Cohort 2: Change from Baseline of Immune Cell Populations

    Change from baseline in immune cell populations will be measured in peripheral blood samples or tissues of healthy volunteers.

    Time frame: Baseline up to 90 days

  2. Cohort 3 and Cohort 4: Change from Baseline of Immune Cell Populations

    Change from baseline in immune cell populations will be measured in peripheral blood samples or tissues of healthy volunteers.

    Time frame: Baseline up to 14 days

  3. Cohort 5: Change from Baseline of Immune Cell Populations

    Change from baseline in immune cell populations will be measured in tissues of healthy volunteers.

    Time frame: Baseline up to 10 days

  4. Cohort 1 and Cohort 2: Change from Baseline in Cell Surface Antigen Phenotype

    Change from baseline in cell surface antigen phenotype will be measured in peripheral blood samples or tissues of healthy volunteers.

    Time frame: Baseline up to 90 days

  5. Cohort 3 and Cohort 4: Change from Baseline in Cell Surface Antigen Phenotype

    Change from baseline in cell surface antigen phenotype will be measured in peripheral blood samples or tissues of healthy volunteers.

    Time frame: Baseline up to 14 days

  6. Cohort 5: Change from Baseline in Cell Surface Antigen Phenotype

    Change from baseline in cell surface antigen phenotype will be measured in tissues of healthy volunteers.

    Time frame: Baseline up to 10 days

  7. Cohort 1 and Cohort 2: Change from Baseline in Activation Status of Inflammatory Mediators (Soluble Cytokines and Chemokines)

    Soluble cytokines and chemokines will be measured by immunoassay.

    Time frame: Baseline up to 90 days

  8. Cohort 3 and Cohort 4: Change from Baseline in Activation Status of Inflammatory Mediators (Soluble Cytokines and Chemokines)

    Soluble cytokines and chemokines will be measured by immunoassay.

    Time frame: Baseline up to 14 days

  9. Cohort 5: Change from Baseline in Activation Status of Inflammatory Mediators (Soluble Cytokines and Chemokines)

    Soluble cytokines and chemokines will be measured by immunoassay.

    Time frame: Baseline up to 10 days

  10. Cohort 1 and Cohort 2: Change from Baseline in Activation Status of Inflammatory Mediators (Cell-bound and Tissue-associated Proteins)

    Cell-bound and tissue-associated proteins will be measured by established methods including flow cytometry and immunohistochemistry.

    Time frame: Baseline up to 90 days

  11. Cohort 3 and Cohort 4: Change from Baseline in Activation Status of Inflammatory Mediators (Cell-bound and Tissue-associated Proteins)

    Cell-bound and tissue-associated proteins will be measured by established methods including flow cytometry and immunohistochemistry.

    Time frame: Baseline up to 14 days

  12. Cohort 5: Change from Baseline in Activation Status of Inflammatory Mediators (Cell-bound and Tissue-associated Proteins)

    Cell-bound and tissue-associated proteins will be measured by established methods including flow cytometry and immunohistochemistry.

    Time frame: Baseline up to 10 days

  13. Cohort 1 and Cohort 2: Change from Baseline in Expression of Inflammatory Mediators

    Transcriptional changes in gene expression will be measured by established methods such as ribonucleic acid (RNA) microarray, RNAseq, and single cell RNA sequencing, and will be reported in number of gene transcripts per sample or per cell.

    Time frame: Baseline up to 90 days

  14. Cohort 3 and Cohort 4: Change from Baseline in Expression of Inflammatory Mediators

    Transcriptional changes in gene expression will be measured by established methods such as ribonucleic acid (RNA) microarray, RNAseq, and single cell RNA sequencing, and will be reported in number of gene transcripts per sample or per cell.

    Time frame: Baseline up to 14 days

  15. Cohort 5: Change from Baseline in Expression of Inflammatory Mediators

    Transcriptional changes in gene expression will be measured by established methods such as RNA microarray, RNAseq, and single cell RNA sequencing, and will be reported in number of gene transcripts per sample or per cell.

    Time frame: Baseline up to 10 days

Secondary outcomes

  1. Change in Standard Deviation from Baseline of Immune Cell Populations Within a Participant

    Change in standard deviation from baseline of immune cell populations within a participant will be measured.

    Time frame: Cohort 1 and Cohort 2: Baseline up to 90 days; Cohort 3 and Cohort 4: Baseline up to 14 days; Cohort 5: Baseline up to 10 days

  2. Change in Standard Deviation from Baseline of Immune Cell Populations Between Participants

    Change in standard deviation from baseline of immune cell populations between participants will be measured.

    Time frame: Cohort 1 and Cohort 2: Baseline up to 90 days; Cohort 3 and Cohort 4: Baseline up to 14 days; Cohort 5: Baseline up to 10 days

  3. Change in Standard Deviation from Baseline in Cell Surface Antigen Phenotype Within a Participant

    Change in standard deviation from baseline in cell surface antigen phenotype within a participant will be measured.

    Time frame: Cohort 1 and Cohort 2: Baseline up to 90 days; Cohort 3 and Cohort 4: Baseline up to 14 days; Cohort 5: Baseline up to 10 days

  4. Change in Standard Deviation from Baseline in Cell Surface Antigen Phenotype Between Participants

    Change in standard deviation from baseline in cell surface antigen phenotype between participants will be measured.

    Time frame: Cohort 1 and Cohort 2: Baseline up to 90 days; Cohort 3 and Cohort 4: Baseline up to 14 days; Cohort 5: Baseline up to 10 days

  5. Change in Standard Deviation from Baseline in Activation Status of Inflammatory Mediators Within a Participant

    Change in standard deviation from baseline in activation status of inflammatory mediators within a participant will be measured.

    Time frame: Cohort 1 and Cohort 2: Baseline up to 90 days; Cohort 3 and Cohort 4: Baseline up to 14 days; Cohort 5: Baseline up to 10 days

  6. Change in Standard Deviation from Baseline in Activation Status of Inflammatory Mediators Between Participants

    Change in standard deviation from baseline in activation status of inflammatory mediators between participants will be measured.

    Time frame: Cohort 1 and Cohort 2: Baseline up to 90 days; Cohort 3 and Cohort 4: Baseline up to 14 days; Cohort 5: Baseline up to 10 days

  7. Change in Standard Deviation from Baseline in Expression of Inflammatory Mediators Within a Participant

    Change in standard deviation from baseline in expression of inflammatory mediators within a participant will be measured.

    Time frame: Cohort 1 and Cohort 2: Baseline up to 90 days; Cohort 3 and Cohort 4: Baseline up to 14 days; Cohort 5: Baseline up to 10 days

  8. Change in Standard Deviation from Baseline in Expression of Inflammatory Mediators Between Participants

    Change in standard deviation from baseline in expression of inflammatory mediators between participants will be measured.

    Time frame: Cohort 1 and Cohort 2: Baseline up to 90 days; Cohort 3 and Cohort 4: Baseline up to 14 days; Cohort 5: Baseline up to 10 days

  9. Correlation of Baseline Immune Cell Populations with Vaccine/Antigen Immune Response Phenotype

    Correlation of baseline immune cell populations with vaccine/antigen immune response phenotype will be measured by phenotypic and functional assays.

    Time frame: Cohort 1 and Cohort 2: Baseline up to 90 days; Cohort 3 and Cohort 4: Baseline up to 14 days

  10. Correlation of Genomics with Vaccine/Antigen Immune Response Phenotype

    Correlation of genomics with vaccine/antigen immune response phenotype will be measured by phenotypic and functional assays.

    Time frame: Cohort 1 and Cohort 2: Baseline up to 90 days; Cohort 3 and Cohort 4: Baseline up to 14 days

  11. Correlation of Serology with Vaccine/Antigen Immune Response Phenotype

    Correlation of serology with vaccine/antigen immune response phenotype will be measured by phenotypic and functional assays.

    Time frame: Cohort 1 and Cohort 2: Baseline up to 90 days; Cohort 3 and Cohort 4: Baseline up to 14 days

  12. Correlation of Soluble Proteins with Vaccine/Antigen Immune Response Phenotype

    Correlation of soluble proteins with vaccine/antigen immune response phenotype will be measured by phenotypic and functional assays.

    Time frame: Cohort 1 and Cohort 2: Baseline up to 90 days; Cohort 3 and Cohort 4: Baseline up to 14 days

07

Study locations

1 site
  • Clinical Pharmacology Unit
    Merksem, 2170, Belgium
08

References and documents

Individual participant data

Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · www.janssen.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2019 to primary completion in Dec 2019, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2019
First posted
May 16, 2019
StartActual
Apr 8, 2019
Primary completionActual
Dec 26, 2019
CompletionActual
Dec 26, 2019
Last update
Feb 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03953196
Responsible party
Sponsor
First posted
May 16, 2019
Start date
Apr 8, 2019
Primary completion
Dec 26, 2019
Completion
Dec 26, 2019
Last update
Feb 3, 2025

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: MVA-BN smallpox vaccine · Shingrix · Lipopolysaccharides · Candida albicans Antigen Injection

Start the discussion